Quviviq (Daridorexant HCl) Patent Expiration, LOE Window & CMS Spending
Quviviq (Daridorexant HCl) by Idorsia: FDA Orange Book core substance LOE 2034-12-02, 0 AB generics, $35.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Idorsia |
| FDA Application & Pathway | N214985 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2034-12-02 |
| Last Listed Patent or Exclusivity Date | 2034-12-02 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $35.5M |
| 2024 Medicare Part D Spend | $24.4M |
| 2024 Medicaid Spend | $11.1M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |